216 related articles for article (PubMed ID: 23879512)
1. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
Mohammadieh AM; Bowler SD; Silverstone EJ; Glanville AR; Yates DH
Med J Aust; 2013 Jul; 199(2):121-3. PubMed ID: 23879512
[TBL] [Abstract][Full Text] [Related]
2. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
[TBL] [Abstract][Full Text] [Related]
3. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
[TBL] [Abstract][Full Text] [Related]
5. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
6. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
7. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
9. [Sporadic Lymphangioleiomyomatosis (sLAM) and Tuberous Sclerosis Complex (TSC) - Pulmonary Manifestations].
Brakemeier S; Grohé C; Bachmann F; Budde K
Pneumologie; 2017 Feb; 71(2):86-95. PubMed ID: 27585353
[TBL] [Abstract][Full Text] [Related]
10. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
11. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
[TBL] [Abstract][Full Text] [Related]
12. Chyloperitoneum, chylothorax and lower extremity lymphedema in woman with sporadic lymphangioleiomyomatosis successfully treated with sirolimus: a case report.
Chachaj A; Drozdz K; Chabowski M; Dziegiel P; Grzegorek I; Wojnar A; Jazwiec P; Szuba A
Lymphology; 2012 Jun; 45(2):53-7. PubMed ID: 23057149
[TBL] [Abstract][Full Text] [Related]
13. [Pulmonary lymphangioleiomyomatosis: From pathogenesis to management].
Chebib N; Khouatra C; Lazor R; Archer F; Leroux C; Gamondes D; Thivolet-Bejui F; Cordier JF; Cottin V
Rev Mal Respir; 2016 Oct; 33(8):718-734. PubMed ID: 26604019
[TBL] [Abstract][Full Text] [Related]
14. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
Taveira-DaSilva AM; Moss J
Clin Epidemiol; 2015; 7():249-57. PubMed ID: 25897262
[TBL] [Abstract][Full Text] [Related]
15. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
16. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
17. A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
Krymskaya VP; Courtwright AM; Fleck V; Dorgan D; Kotloff R; McCormack FX; Kreider M
Respir Med; 2020 Mar; 163():105898. PubMed ID: 32125970
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Wang Q; Luo M; Xiang B; Chen S; Ji Y
Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
[TBL] [Abstract][Full Text] [Related]
19. Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis.
Namba M; Masuda T; Nakamura T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Intern Med; 2017 Dec; 56(24):3327-3331. PubMed ID: 29021448
[TBL] [Abstract][Full Text] [Related]
20. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]